

# Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE

Erik W Anderson <sup>1</sup>, Ying Jin,<sup>2</sup> Andrew Shih,<sup>3</sup> Arnon Arazi,<sup>1</sup> Sara Goodwin,<sup>2</sup> Julien Roeser,<sup>4</sup> Richard A Furie <sup>1,5</sup>, Cynthia Aranow <sup>1</sup>, Bruce Volpe,<sup>1</sup> Betty Diamond <sup>1</sup>, Meggan Mackay<sup>1</sup>

**To cite:** Anderson EW, Jin Y, Shih A, *et al.* Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. *Lupus Science & Medicine* 2022;9:e000808. doi:10.1136/lupus-2022-000808

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/lupus-2022-000808>).

Received 18 August 2022  
Accepted 2 November 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Erik W Anderson;  
eanderson22@northwell.edu

## ABSTRACT

**Objective** Quinolinic acid (QA), a kynurenine (KYN)/tryptophan (TRP) pathway metabolite, is an N-methyl-D-aspartate receptor agonist that can produce excitotoxic neuron damage. Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction. We determined whether peripheral blood interferon-stimulated gene (ISG) expression associates with elevated serum KYN:TRP and QA:KA ratios in SLE.

**Methods** ISG expression (whole-blood RNA sequencing) and serum metabolite ratios (high-performance liquid chromatography) were measured in 72 subjects with SLE and 73 healthy controls (HCs). ISG were identified from published gene sets and individual IFN scores were derived to analyse associations with metabolite ratios, clinical parameters and neuropsychological assessments. SLE analyses were grouped by level of ISG expression ('IFN high', 'IFN low' and 'IFN similar to HC') and level of monocyte-associated gene expression (using CIBERSORTx).

**Results** Serum KYN:TRP and QA:KA ratios were higher in SLE than in HC ( $p < 0.01$ ). 933 genes were differentially expressed  $\geq 2$ -fold in SLE versus HC ( $p < 0.05$ ). 70 of the top 100 most highly variant genes were ISG. Approximately half of overexpressed genes that correlated with KYN:TRP and QA:KA ratios ( $p < 0.05$ ) were ISG. In 36 IFN-high subjects with SLE, IFN scores correlated with KYN:TRP ratios ( $p < 0.01$ ), but not with QA:KA ratios. Of these 36 subjects, 23 had high monocyte-associated gene expression, and in this subgroup, the IFN scores correlated with both KY:NTRP and QA:KA ratios ( $p < 0.05$ ).

**Conclusions** High ISG expression correlated with elevated KYN:TRP ratios in subjects with SLE, suggesting IFN-mediated KYN/TRP pathway activation, and with QA:KA ratios in a subset with high monocyte-associated gene expression, suggesting that KYN/TRP pathway activation may be particularly important in monocytes. These results need validation, which may aid in determining which patient subset may benefit from therapeutics directed at the IFN or KYN/TRP pathways to ameliorate a potentially neurotoxic QA/KA imbalance.

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Type I and II interferons (IFNs) contribute to SLE pathogenesis and stimulate the kynurenine (KYN)/tryptophan (TRP) pathway, producing elevated quinolinic acid (QA) relative to kynurenic acid (KA).
- ⇒ An elevated QA:KA ratio, a potential neurotoxic imbalance, associated with poor working memory performance in subjects with SLE when controlling for other factors known to affect cognition.

## WHAT THIS STUDY ADDS


- ⇒ High IFN-stimulated gene expression in subjects with SLE correlated with elevated KYN:TRP ratios, suggesting IFN-mediated KYN/TRP pathway activation, and with elevated QA:KA ratios in a subset of subjects with SLE with high monocyte-associated gene expression.
- ⇒ These results support IFN-mediated KYN/TRP pathway activation in SLE and suggest that this pathway may be particularly important in monocytes.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ These results require further validation in a separate cohort and may help identify which subset of patients with SLE may benefit from therapeutics targeting the IFN or KYN/TRP pathways to ameliorate a potentially neurotoxic QA/KA imbalance.

## INTRODUCTION

Cognitive dysfunction (CD) is highly prevalent in SLE with significant impact on quality of life.<sup>1</sup> Quinolinic acid (QA), a metabolite of the kynurenine (KYN)/tryptophan (TRP) pathway, is a N-methyl-D-aspartate receptor (NMDAR) agonist that can cause excessive glutamatergic excitotoxicity to neurons<sup>2</sup> and may contribute to CD in SLE. The first step in the KYN/TRP pathway is regulated by indoleamine 2,3-dioxygenase (IDO1), an enzyme



**Figure 1** The kynurenine/tryptophan pathway.<sup>1</sup> This is a simplified schematic of the KYN/TRP pathway, highlighting the intermediates and enzymes involved in the production of QA and KA. The enzyme IDO1 is stimulated by inflammatory cytokines, such as IFN, that results in the breakdown of TRP into KYN. KYN may be further metabolised by KMO ultimately to QA, an NMDAR agonist, or by KAT to KA, an NMDAR antagonist. Since the enzyme KMO has higher affinity for KYN than KAT, metabolism proceeds preferentially towards the production of QA in the setting of inflammation.<sup>2 26 61</sup> IDO1, indolamine 2, 3-dioxygenase; IFN- $\alpha$ , interferon alpha; IFN- $\gamma$ , interferon gamma; KA, kynurenic acid; KMO, kynurenine 3-monooxygenase; NMDAR, N-methyl-D-aspartate receptor; QA, quinolinic acid; TNF- $\alpha$ , tumour necrosis factor alpha.

that is readily induced by interferons (IFNs) that are also highly associated with SLE pathogenesis and possibly with disease subtypes.<sup>3,4</sup> The objective of this study was to investigate whether serum levels of KYN/TRP pathway metabolites, including the potentially neurotoxic QA, correlate with peripheral blood type I (interferon alpha (IFN- $\alpha$ )) and type II (interferon gamma (IFN- $\gamma$ )) interferon-stimulated gene (ISG) expression in SLE.

The enzyme IDO1 is present in most tissues and immune cells including monocytes, dendritic cells and microglia.<sup>5</sup> IDO1 is most highly expressed during inflammation,<sup>5</sup> and activation by IFN- $\gamma$ , IFN- $\alpha$ , tumour necrosis factor alpha and interleukin-6<sup>6–8</sup> stimulates TRP degradation to KYN.<sup>7</sup> KYN is further metabolised to QA and kynurenic acid (KA), an NMDAR antagonist with potential to protect neurons from excitotoxic damage<sup>2</sup> (figure 1). Under inflammatory conditions, increased QA production relative to KA results in a potential neurotoxic imbalance,<sup>2</sup> and an elevated serum QA:KA ratio may be a marker for central NMDAR activation and neurotoxicity. IDO1 expression in monocytes is strongly induced by IFN, including IFN- $\alpha$ ,<sup>9,10</sup> and monocytes have been reported to be more potent QA producers than microglia.<sup>11 12</sup>

Both peripheral and central IDO1 activation by IFN may increase KYN/TRP pathway activation and contribute to elevated QA in the central nervous system (CNS). Some cytokines, including both type I and II IFNs, can cross an intact blood–brain barrier (BBB).<sup>2 13</sup> KYN and TRP also easily cross an intact BBB, in contrast to the metabolites QA and KA that cross relatively poorly.<sup>2,14</sup> Nonetheless, several human studies report positive correlations between QA levels in blood and cerebrospinal fluid (CSF).<sup>15–17</sup> Recent evidence of a disrupted BBB in SLE<sup>18 19</sup> suggests that peripheral molecules may more readily access the CNS with subsequent effects on neurons and/or microglia.<sup>2 20</sup>

An imbalance in QA relative to KA is implicated in the pathogenesis of CD in other neurodegenerative diseases, idiopathic depression and suicidal ideation, and

depression related to IFN- $\alpha$  treatment for hepatitis C.<sup>221–24</sup> In subjects with SLE, elevated serum QA is reported,<sup>25–27</sup> which correlated with CSF levels.<sup>25</sup> Additionally, we have reported a significant association between elevated serum QA:KA ratios and poor working memory performance in subjects with SLE when controlling for other factors known to affect cognition.<sup>26</sup>

The IFN pathway is recognised as a fundamental pathological mechanism in SLE supported, in part, by the clinical efficacy of an anti-type I IFN receptor monoclonal antibody.<sup>3 28</sup> Due to the poor sensitivity and specificity of assays measuring IFN levels directly, most human SLE studies have measured IFN indirectly by quantifying ISG expression, collectively called the ISG signature. Multiple methodologies have been used to define the ISG signature in whole blood and specific cell types; however, there is no consensus as to which ISG best associates with functional biological processes driven by IFN.<sup>3</sup> There is also a significant overlap between type I and type II ISG signatures in SLE.<sup>29</sup> Pertinent to our study, it has been previously reported that serum KYN/TRP levels correlated with type I IFN activity measured by a WISH cell reporter assay.<sup>7</sup>

We have previously demonstrated elevated serum KYN:TRP and QA:KA ratios in SLE<sup>26</sup> and speculated that this may have been a result of IFN-mediated IDO1 induction. Using RNA sequencing (RNAseq) for quantification of peripheral blood gene expression, we sought to determine relationships between whole-blood ISG expression and serum KYN:TRP and QA:KA ratios in subjects with SLE versus healthy controls (HCs). We hypothesised that ISG expression would correlate with KYN/TRP pathway metabolites. Given the results of in vitro studies revealing more effective IFN-mediated IDO1 induction in monocytes rather than lymphocytes,<sup>9 30–33</sup> we also examined the relationship between ISG expression and elevated KYN:TRP and QA:KA ratios as a function of peripheral monocyte-associated gene expression.

## METHODS

### Study design, subject selection and assessments

For this cross-sectional study, 72 female subjects with SLE were recruited from the Northwell Health Rheumatology Clinics as part of a previously described cohort.<sup>26</sup> All were  $\geq 18$  years old and fulfilled either the American College of Rheumatology or Systemic Lupus International Collaborating Clinics criteria for SLE.<sup>34,35</sup> Seventy-three female HCs, comparable to subjects with SLE in age, ethnicity and race, were recruited to the same cohort.<sup>26</sup> SLE disease activity was assessed using the SELENA-SLEDAI (SLE Disease Activity Index),<sup>36</sup> and blood was drawn from all subjects into PAXgene tubes, frozen and stored for analysis. For all subjects, cognition was assessed using the Automated Neuropsychological Assessment Metrics (ANAM) computerised test battery and a 2x2 array to assess object recognition and spatial memory, as previously described.<sup>37</sup> Throughput scores (accuracy÷reaction time) were the primary measures of cognitive efficiency. Depression was assessed using the Beck Depression Inventory.<sup>38</sup> Testing was administered in a quiet room to minimise distractions. All blood collections, clinical and neuropsychological assessments were performed within a 10-day period.

### Patient and public involvement

Patients were not directly involved in the design, recruitment or conduct of the study.

### Measurement of KYN/TRP pathway metabolites

Metabolite concentrations in deidentified, blinded serum samples were measured by Charles River Laboratories (www.criver.com) using high-performance liquid chromatography with tandem mass spectrometry (online supplemental methods, A).

### RNA sequencing

Deidentified, blinded whole-blood samples in PAXgene Blood RNA tubes were shipped to Cold Spring Harbour Laboratory, New York, frozen on dry ice, for RNAseq analysis. Details of RNA isolation and quality control measures, as well as library preparation and RNAseq technique, are described in online supplemental methods, B.

### Statistical analyses

#### Gene expression analysis

RNAseq analysis compared global gene expression profiles of subjects with SLE versus HC. STAR V.2.6.1<sup>39</sup> index was created based on the human GRCh38 Ensembl genome and gene annotations. Single-end 76-base pair reads were directly mapped to this index with command line option ‘-outFilterMismatchNmax 3 outFilterMultiMapNmax 20 -winAnchorMultimapNmax 50’. FeatureCounts software package V.2.0.0<sup>40</sup> was then used to estimate relative gene expressions with parameter setting ‘-fraction -minOverlap 10’ on the alignments generated by STAR. All genes with at least one of the libraries above zero reads were compared between SLE and HC using DESeq2.<sup>41</sup> Differentially expressed genes were defined

as a fold change of  $\geq 2$ ; p value adjusted for multiple comparisons of  $< 0.05$ . A heat map was constructed to represent differentially expressed genes in SLE versus HC. Gene ontology (GO) term enrichment analysis was performed using DAVID Functional Annotation Tool.<sup>42</sup> The complete list of GO term categories with significant enrichment was extracted. An unsupervised principal component analysis (PCA) was performed to evaluate gene expression differences between subjects with SLE and HC, and among subjects with SLE only.

### Identification of ISGs, derivation of IFN scores and derivation of ISG expression subgroups

ISGs were identified from published ISG sets from Arazi *et al.*<sup>43</sup> in their study of IFN response in infiltrating cells in lupus nephritis (n=110 ISG), Chiche *et al.*<sup>29</sup> in their characterisation of the whole-blood IFN signature (n=148 ISG) and the Interferome database<sup>44</sup> (online supplemental methods, C).

IFN scores were derived for each subject to quantify individual total ISG expression for analyses of associations with metabolite ratios and clinical parameters. Individual ISG expression was quantified using z-scores of normalised and variance stabilised gene expression (Z-IFN score) (online supplemental methods, D1). Due to the absence of a ‘standard ISG signature for IFN- $\alpha$ ’, two Z-IFN scores were determined for each subject. An ‘ISG-A score’ was derived from the 110 ISG reported by Arazi *et al.*<sup>43</sup> which included ISGs responsive to both type I and II IFN. A ‘19 type I ISG score’ was derived from a subset of 19 of the 110 ISG reported as more responsive to type I than to type II IFN, according to Chiche *et al.*<sup>29</sup> (online supplemental methods, D2).

The distribution of Z-IFN scores in subjects with SLE, compared with the distribution in HC, was used to determine SLE subgroups based on ISG expression levels. These IFN subgroups were defined as ‘IFN high’ for subjects with a Z-IFN score of  $\geq 2$ , ‘IFN low’ for subjects with a Z-IFN score of  $\geq 1$  to  $< 2$ , and ‘IFN similar to HC’ for subjects with a Z-IFN score of  $< 1$ .

### Cell-type deconvolution using CIBERSORTx and derivation of monocyte-associated gene expression subgroups

Whole-blood, bulk RNAseq expression was deconvolved into single-cell proportions using CIBERSORTx,<sup>45</sup> which provided the relative cell fractions out of 22 immune cell subtypes that are actively involved in innate and adaptive immunity. The distribution of monocyte-associated gene expression in subjects with SLE was compared with the distribution in HC to determine subgroups of subjects with SLE based on the level of monocyte-associated gene expression. As the distribution of monocyte-associated gene expression in subjects with SLE was similar to HC, high monocyte-associated gene expression (‘monocyte high’) was defined as expression of  $> \text{HC mean}$ , while low monocyte-associated gene expression (‘monocyte low’) was defined as expression of  $\leq \text{HC mean}$ .

### Clinical, neuropsychological testing and metabolite associations with gene expression

Differences in subject characteristics, metabolite ratios, and monocyte-associated gene expression between SLE and HC subjects were assessed using t-tests, Mann-Whitney U tests or  $\chi^2$  tests. Differences in neuropsychological test performance among subjects with SLE grouped by IFN scores and monocyte-associated gene expression were assessed using t-tests or Mann Whitney U tests. Spearman's correlations ( $r_s$ ) were used to evaluate relationships between metabolite ratios (KYN:TRP and QA:KA) and IFN scores, between monocyte-associated gene expression and peripheral blood monocyte counts, and among SELENA-SLEDAI scores, IFN scores, monocyte-associated gene expression and metabolite ratios. Significant correlations had a p value of <0.05. Correction for multiple comparisons was performed using Benjamini-Hochberg procedure with a false discovery rate of  $\leq 0.1$ . A more permissive false discovery rate was chosen because the risk of missing a potentially important association (false negative) is greater than the risk of a false association (false positive), given that this is the first study to evaluate the relationship between ISG expression and both KYN:TRP and QA:KA ratios in patients with SLE. Differences in SELENA-SLEDAI scores among the IFN-high, IFN-low and IFN similar to HC subgroups of subjects with SLE were assessed using a Kruskal-Wallis test with a post hoc Dunn-Bonferroni correction for multiple comparisons. GO database was used to identify biological processes associated with genes other than ISG that positively correlated with the KYN:TRP and QA:KA ratios.

## RESULTS

### Subject characteristics and KYN/TRP pathway metabolite ratios

Subjects with SLE demonstrated significantly higher serum KYN:TRP and QA:KA ratios compared with HC (table 1). Subjects with SLE were racially diverse, reflective of disease demographics, with a wide range of disease activity (SLEDAI scores ranging 0–29) and medication use. There were no demographic differences between SLE and HC.

### Peripheral blood gene expression in subjects with SLE and HCs

Differential gene expression analysis revealed 933 genes with  $\geq 2$ -fold differential expression in SLE versus HC, with 762 genes overexpressed and 171 underexpressed ( $p < 0.05$ ). ISG expression was analysed using two approaches. One approach included 110 ISG that respond to stimulation with both type I and II IFNs (termed ISG-A). The second approach included 19 of these 110 ISG that have been shown to be preferentially induced by type I IFN greater than type II IFN.<sup>29</sup> The two approaches were chosen to determine whether type I IFN, given its association with SLE pathogenesis and as a treatment target, demonstrated similar associations with KYN/TRP pathway activation as type I and II IFNs combined. Of the 110 ISG-A,<sup>43</sup> 108 had  $\geq 2$ -fold higher expression in SLE versus HC (mean fold change $\pm$ SD=3.1 $\pm$ 3.0, range=1.2–28.0) (figure 2). IDO1 was one of two ISGs from this set not significantly differentially expressed in SLE versus HC. The majority of subjects with SLE (59/72, 82%) had

**Table 1** Characteristics of subjects with SLE and HCs and KYN:TRP pathway metabolite ratios

Subject characteristics	SLE (N=72)	HC (N=73)	P value
Age (years), mean $\pm$ SD (range)	37.9 $\pm$ 9.6 (22–57)	36.2 $\pm$ 9.5 (18–55)	0.28
Ethnicity (Hispanic/Latino), n (%)	13 (18.1)	13 (17.8)	0.97
Race, n (%)			0.91
Black	43 (59.7)	41 (56.2)	
White	16 (22.2)	18 (24.7)	
Other	13 (18.1)	14 (19.2)	
KYN:TRP ratio, median $\pm$ IQR (range)	0.04 $\pm$ 0.03 (0.01–0.23)	0.03 $\pm$ 0.01 (0.01–0.13)	<0.01
QA:KA ratio, median $\pm$ IQR (range)	18.4 $\pm$ 14.7 (4.0–121.2)	8.9 $\pm$ 5.8 (2.9–45.9)	<0.01
Disease duration, mean $\pm$ SD (range)	12.3 $\pm$ 8.5 (1–38)	n/a	n/a
SELENA SLEDAI score, mean $\pm$ SD (range)	5.4 $\pm$ 5.1 (0–29)	n/a	n/a
Prednisone dose (mg/day), median $\pm$ SD (range)	2.5 $\pm$ 10.0 (0–75)	n/a	n/a
Current hydroxychloroquine use, n (%)	54 (75.0)	n/a	n/a
Current immunosuppressant use, n (%)	34 (47.2)	n/a	n/a
Anti-dsDNA positive (>29 IU/mL), n (%)	50 (69.4)	n/a	n/a
C3 low (<81 mg/dL), n (%)	28 (38.9)	n/a	n/a
C4 low (<13 mg/dL)	24 (33.3)	n/a	n/a

All data are reported either as a mean (or median where indicated) $\pm$ SD (or IQR), or as a frequency (%). All data refer to those which were collected at the time of evaluation.

HC, healthy control; KYN, kynurenine; n/a, not applicable; TRP, tryptophan.



**Table 2** Correlations between IFN scores and serum KYN/TRP pathway metabolite levels in subjects with SLE according to ISG expression subgroup

ISG expression subgroup	IFN score method (z-scores)	KYN/TRP ( $r_s$ )	P value	QA/KA ( $r_s$ )	P value
IFN high (n=36)	ISG-A	0.490	0.002*	0.129	0.453
	19 type I ISG	0.487	0.003*	0.216	0.205
IFN low (n=23)	ISG-A	-0.174	0.427	-0.286	0.187
	19 type I ISG	0.269	0.215	-0.210	0.335
IFN similar to HC(n=13)	ISG-A	0.170	0.578	-0.126	0.681
	19 type I ISG	0.242	0.426	0.000	1.000

Subjects with SLE were assigned to one of three subgroups: 'IFN high' (Z-IFN score  $\geq$ SD above HC mean), 'IFN low' (Z-IFN score  $\geq$ 1 to  $<$ 2) or 'IFN similar to HC' (Z-IFN score  $<$ 1). In each subgroup, correlations between IFN scores (derived from ISG-A and the 19 type I ISG) and metabolite ratios are displayed.

\*Remained significant after Benjamini-Hochberg correction for multiple comparisons.

HC, healthy control; IFN, interferon; ISG, interferon-stimulated gene; KA, kynurenic acid; KYN, kynurenine; QA, quinolinic acid;  $r_s$ , Spearman correlation; TRP, tryptophan.

of SLE-associated clinical variables, as no significant correlations were found between KYN:TRP ratios and SELENA-SLEDAI scores, anti-double stranded DNA, complement, or prednisone dose in this subgroup. No correlations were found between IFN scores and QA:KA ratios in the 3 SLE groups (table 2). Of note, there was no correlation between the IFN scores and metabolite ratios when the IFN-high and IFN-low subjects were combined into one group (n=59; data not shown), suggesting that the correlation between the IFN scores and the metabolite ratios is specific to the IFN-high group.

### Relationships between ISG expression and KYN:TRP pathway metabolite ratios in subjects with SLE stratified by monocyte-associated gene expression

Consistent with previous CIBERSORT studies in SLE,<sup>4647</sup> we found increased relative expression of monocyte-associated genes in SLE (mean $\pm$ SD=0.188 $\pm$ 0.072, range 0.010–0.362) versus HC (mean $\pm$ SD=0.158 $\pm$ 0.042, range 0.049–0.275) (p=0.003) that correlated with peripheral absolute monocyte counts from the complete blood count ( $r_s$ =0.333, p=0.005). Of the 36 subjects with IFN-high SLE using ISG-A, 23 had relatively high monocyte-associated gene expression. In this subgroup, IFN scores

**Table 3** Correlations between IFN scores and serum KYN/TRP pathway metabolite levels in subjects with SLE according to ISG and monocyte-associated gene expression subgroups

ISG expression subgroup	Monocyte-associated gene expression subgroup	IFN score method (z-scores)	KYN/TRP ( $r_s$ )	P value	QA/KA ( $r_s$ )	P value
IFN high (n=36)	Monocyte high (n=23)	ISG-A	0.504	0.014*	0.429	0.041*
		19 type I ISG	0.532	0.009*	0.419	0.046*
	Monocyte low (n=13)	ISG-A	0.440	0.133	-0.132	0.668
		19 type I ISG	0.330	0.271	0.044	0.887
IFN low (n=23)	Monocyte high (n=17)	ISG-A	-0.289	0.260	-0.326	0.202
		19 type I ISG	0.336	0.188	-0.252	0.328
	Monocyte low (n=6)	ISG-A	0.547	0.261	0.137	0.796
		19 type I ISG	0.429	0.396	0.073	0.890
IFN similar to HC (n=13)	Monocyte high (n=8)	ISG-A	-0.071	0.867	-0.199	0.637
		19 type I ISG	0.048	0.911	-0.024	0.955
	Monocyte low (n=5)	ISG-A	0.785	0.116	0.110	0.861
		19 type I ISG	0.500	0.391	0.100	0.873

In addition to the ISG expression subgroups previously described in table 2, subjects with SLE were further designated as either 'monocyte high' (monocyte-associated gene expression  $>$ HC mean) or 'monocyte low' (monocyte-associated gene expression  $\leq$ HC mean). In each subgroup, correlations between both IFN scores (derived from ISG-A and the 19 type I ISG) and metabolite ratios are displayed.

\*Remained significant after Benjamini-Hochberg correction for multiple comparisons.

HC, healthy control; IFN, interferon; ISG, interferon-stimulated gene; KYN, kynurenine; QA, quinolinic acid; TRP, tryptophan.

correlated significantly with both KYN:TRP and QA:KA ratios (table 3). These correlations between IFN scores and metabolite ratios were independent of other SLE-associated variables, such as SELENA-SLEDAI scores, anti-doublestranded DNA, complement or prednisone dose. Conversely, IFN scores in the 13 IFN-high SLE with relatively lower monocyte-associated gene expression did not correlate with KYN:TRP or QA:KA ratios (table 3). Among subjects with SLE who were classified as IFN low or IFN similar to HC, no significant correlations were identified between IFN scores and metabolite ratios, regardless of the level of monocyte-associated gene expression.

### Correlations between SLE disease activity and IFN scores, monocyte-associated gene expression, KYN:TRP pathway metabolite ratios

Consistent with prior reports,<sup>3 29</sup> both IFN scores (ISG-A and 19 type I ISG) positively correlated with disease activity measured by SELENA-SLEDAI ( $r_s=0.237$ ,  $p=0.045$ ; ISG-A and  $r_s=0.240$ ,  $p=0.042$ ; 19 type I ISG). Additionally, SELENA-SLEDAI scores were significantly higher in subjects with SLE classified as IFN high ( $6.4\pm 5.6$ , range 0–29) compared with subjects with SLE classified as IFN similar to HC ( $2.2\pm 2.2$ , range 0–6) ( $p=0.009$ ). SELENA-SLEDAI scores in IFN low SLE ( $5.6\pm 4.9$ , range 0–21) were not significantly different from IFN similar to HC ( $p=0.073$ ) or IFN high ( $p=1.000$ ). SELENA-SLEDAI scores correlated modestly with QA:KA ratios ( $r_s=0.238$ ,  $p=0.044$ ), while they did not correlate with KYN:TRP ratios ( $r_s=0.002$ ,  $p=0.990$ ). Neither the monocyte-associated gene expression score ( $r_s=0.238$ ,  $p=0.044$ ) nor peripheral monocyte counts ( $r_s=-0.051$ ,  $p=0.672$ ) correlated with SELENA-SLEDAI. Of note, all correlations between IFN scores and metabolite ratios and SLEDAI scores were significant using a false discovery rate of 0.05, except the correlations between IFN scores and QA:KA ratios in the subjects with both high IFN scores and high monocyte-associated gene expression ( $n=23$ , table 3); these correlations were significant using a false discovery rate of 0.10.

### Associations between neuropsychological test performance, IFN scores and monocyte-associated gene expression

Neuropsychological test performance was compared between the IFN high ( $n=36$ ) and other subjects with SLE (IFN low+IFN similar to HC,  $n=36$ ). There were no significant differences in cognitive scores including the ANAM subtests or 2x2 array or Beck Depression Inventory scores (all  $p>0.05$ ). Comparison of neuropsychological test performance between subjects in the IFN-high and monocyte-high subgroups ( $n=23$ ) and all other subjects with SLE ( $n=49$ ) also found no significant differences in cognitive test scores (ANAM subtests and 2x2 array) or Beck Depression Inventory scores between these groups (all  $p>0.05$ ).

## DISCUSSION

We report elevated ISG expression in SLE compared with HC that correlates with KYN/TRP pathway metabolites.

The association between elevated ISG expression and an elevated KYN:TRP ratio corroborates evidence of IFN-mediated IDO1 induction from one previous study in subjects with SLE,<sup>7</sup> and this is the first report of an association between elevated ISG expression and elevated QA:KA ratios, representing a potential neurotoxic imbalance that may contribute to cognitive impairment in SLE. The majority of ISG that correlated with KYN:TRP and QA:KA were type I ISG (89% and 82%, respectively), the predominant IFN associated with SLE pathogenesis. We observed that ISG expression correlated with both the KYN:TRP and QA:KA ratios in subjects with SLE with high monocyte-associated gene expression, consistent with in vitro studies demonstrating that IFN-induced KYN/TRP pathway activation is particularly important in monocytes.<sup>9 30–33</sup> In aggregate, these results support our hypothesis that IFN-mediated KYN/TRP pathway activation contributes to elevated KYN:TRP and QA:KA ratios observed in patients with SLE.

The IFN scores correlated with KYN:TRP ratios in a subgroup of subjects with IFN-high SLE, but not with KYN:TRP ratios in SLE subgroups of IFN low or IFN expression similar to HC, suggesting IFN-induced IDO1 activation. It is conspicuous that IDO1 was among only two genes of the 110 ISG-A<sup>43</sup> not differentially expressed in SLE versus HC. This finding conflicts with multiple studies demonstrating increased peripheral IDO1 activity in SLE versus HC,<sup>7 48 49</sup> including one report that SLE sera increased IDO1 expression in a type I IFN-dependent manner.<sup>7</sup> It is possible that IDO1 activity may vary based on SLE disease activity and medication use,<sup>48–51</sup> which may have impacted IDO1 expression in our cohort. It is also possible that IDO1 expression is short-lived compared with protein expression (metabolite ratios) in the peripheral blood, and compensatory downregulation of IDO1 expression was captured by our measurement.

Despite a significant correlation between ISG expression and KYN:TRP ratios in the IFN-high SLE subgroup, ISG expression did not correlate with QA:KA ratios in this subgroup. Enzymes downstream of IDO1 in the KYN/TRP pathway, kynurenine 3-monooxygenase (KMO) and kynurenine aminotransferase (figure 1) lead to the production of QA and KA, respectively. However, genes encoding these enzymes were not differentially expressed in SLE versus HC (data not shown), suggesting that alteration of downstream enzymatic activity did not play a role in the lack of association with QA:KA. Nevertheless, in a subgroup of the 36 subjects with IFN-high SLE with high monocyte-associated gene expression, ISG expression did correlate with QA:KA ratios, suggesting that circulating monocytes may be important in IFN-mediated IDO1 induction. In vitro studies of cultured monocytes demonstrate expression of IDO1 and downstream KYN/TRP pathway enzymes (KMO and kynureninase, figure 1), resulting in the production of QA<sup>30 31</sup> and a correspondingly elevated QA:KA ratio<sup>32</sup> in response to stimulation by IFN- $\gamma$  or toll-like receptor agonists. In contrast, IDO1 in B lymphocytes or T lymphocytes is poorly expressed,<sup>9 31</sup>

and stimulation of cultured B cells or T cells with IFN- $\gamma$  produces little to no KYN and no QA.<sup>31 33</sup> Further, recent single-cell RNAseq studies of peripheral blood mononuclear cells (PBMCs) in subjects with SLE revealed monocytes as the largest fraction of cell types with high ISG expression, and these ISG-expressing monocytes were enriched in those with the highest disease activity.<sup>52 53</sup> In our study, we propose that high monocyte-associated gene expression, which correlated with high peripheral monocyte counts, suggests greater peripheral IDO1 which, in the setting of high IFN, leads to an elevated QA:KA ratio. Therefore, this potential relationship between monocytes and IFN-mediated induction of the KYN/TRP pathway in SLE, leading to an elevated QA:KA ratio, deserves further study.

We found that 19 of the 110 ISG-As that are reported to be more responsive to type I than type II IFN displayed similar correlations with the metabolite ratios compared with all 110 ISGs. This suggests that type I IFN may be important in IDO1 induction in SLE, leading to high metabolite ratios. Nevertheless, type II IFN is a strong inducer of the pathway *in vitro* and is reported by some to induce IDO1 more strongly than type I IFN.<sup>54</sup> Since 104 of the 110 ISG-As (95%) are stimulated by both type I and II IFNs, it is difficult to infer which class of IFN is more highly associated with the elevated metabolite ratios observed in this study.

There are several potential limitations to this study. ISG expression, metabolite ratios and monocyte-associated gene expression were measured in peripheral blood rather than in CSF or brain tissue, which may be more representative of KYN/TRP pathway activation in the brain. However, KYN easily crosses the BBB<sup>2</sup>; the peripheral KYN/TRP pathway activation contributes to elevated levels of KYN, QA and KA in the CNS in animal models,<sup>55 56</sup> and multiple studies report that peripheral KYN/TRP pathway metabolites in humans correlate with CSF levels.<sup>15 16 57 58</sup> Additionally, both type I and II IFNs can cross the BBB.<sup>13</sup> Type I IFN was measured indirectly with ISG, while newer technologies such as single-molecule array digital ELISA are now sensitive to IFN- $\alpha$  without cross-reactivity for other IFN species.<sup>59</sup> These techniques can be applied in future studies using stored sera. RNAseq of whole-blood samples precludes the ability to accurately determine the contribution of individual cells to gene expression. While deconvolution methods, such as CIBERSORT used in this study, can estimate cell-type proportions from bulk RNAseq data and have been applied in studies involving subjects with SLE,<sup>46 47</sup> sorting of PBMCs by flow cytometry or the use of single-cell RNAseq offer distinct advantages over deconvolution methods. Single-cell RNAseq enables measurement of the transcriptome in individual cells and may allow better characterisation of the heterogeneity of gene expression within cell types. Nevertheless, the CIBERSORTx method leverages single-cell RNAseq-derived reference profiles to perform the deconvolution<sup>60</sup> and has been validated using sorted cells via flow cytometry, showing that

cell-type fraction estimates from deconvolution correlates with sorted cell fractions.<sup>60</sup> Our analyses led to observations regarding associations between circulating monocytes and IDO1 activation; however, activated monocytes migrate into tissue, and our analysis of whole blood in isolation may not provide a comprehensive analysis of the relationship between monocytes and IFN induction of the KYN/TRP pathway. As IDO1-expressing monocytes can potentially enter the CNS under inflammatory conditions following BBB disruption and contribute to excess KYN/TRP pathway metabolites in the brain,<sup>12</sup> it would be particularly relevant to determine ISG expression in monocytes directly and analyse associations with the KYN/TRP pathway metabolites. Future studies using sorted cells or single-cell RNAseq can be employed to validate our results. Our ability to test associations of ISG expression and monocyte-associated gene expression with neuropsychological performance was limited by the relatively small number of subjects with both high-IFN and high monocyte-associated gene expression; however, future studies with adequate power to test these associations are planned. Finally, many medications can inhibit IDO1 activity, including antimalarials, immunosuppressants and corticosteroids,<sup>50 51</sup> and this may have contributed to the lack of differential IDO1 expression in SLE versus HC. However, excluding subjects based on these medications would have severely limited the study's feasibility and generalisability.

This is the first study in patients with SLE to examine relationships between ISG expression, KYN/TRP pathway activation and elevated QA:KA ratios. In peripheral blood, elevated ISG expression correlates with an elevated KYN:TRP ratio, suggesting IDO1 induction, and correlates with an elevated QA:KA ratio in subjects with SLE with high IFN scores and monocyte-associated gene expression. These results support our overarching hypothesis that IFN-stimulated IDO1 activation leads to increased production of KYN/TRP metabolites with potential impact on neurological function and cognition.<sup>26</sup> These results need validation in a separate cohort, and a potential relationship between monocytes and IFN-mediated IDO1 induction in patients with SLE needs to be clarified. These further studies may aid in determining which subjects may benefit from therapeutics directed at the IFN or KYN/TRP pathways to ameliorate a potentially neurotoxic QA/KA imbalance in a personalised medicine approach.

#### Author affiliations

<sup>1</sup>Institute of Molecule Medicine, The Feinstein Institutes for Medical Research, Manhasset, New York, USA

<sup>2</sup>Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA

<sup>3</sup>Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, New York, USA

<sup>4</sup>Charles River Laboratories, South San Francisco, California, USA

<sup>5</sup>Rheumatology, Northwell Health, Great Neck, New York, USA

**Acknowledgements** The authors express their gratitude towards the patients and healthy individuals who participated in this study, and the support of the research coordinators and nurses at the Feinstein Institutes.

**Contributors** Study design: EWA, MM, CA and BD. Data collection: EWA, YJ, AS, SG, MM, CA, RAF and JR. Data analysis: EWA, YJ, AS, MM, CA, BD, BV and JR. Interpretation of findings: EWA, YJ, AA, MM, CA, BD and BV. Preparation of the manuscript: EWA, YJ, AA, MM, CA, BD, BV and JR. Guarantor: EWA. All authors read and approved the final manuscript.

**Funding** This work was supported by a grant from the Lupus Foundation of America (Gary S. Gilkeson Career Development Award, G-1904-00773, PI: EWA, MD, PhD; October 2019–September 2021).

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by Northwell Health Institutional Review Board (ID: 17-0389). The participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Erik W Anderson <http://orcid.org/0000-0003-3154-9648>

Richard A Furie <http://orcid.org/0000-0001-6712-1585>

Cynthia Aranow <http://orcid.org/0000-0001-9299-0053>

Betty Diamond <http://orcid.org/0000-0002-3250-3804>

#### REFERENCES

- Kello N, Anderson E, Diamond B. Cognitive dysfunction in systemic lupus erythematosus: a case for initiating trials. *Arthritis Rheumatol* 2019;71:1413–25.
- Schwarcz R, Stone TW. The kynurenine pathway and the brain: challenges, controversies and promises. *Neuropharmacology* 2017;112:237–47.
- Rönblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. *Lupus Sci Med* 2019;6:e000270.
- Oke V, Gunnarsson I, Dorschner J, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. *Arthritis Res Ther* 2019;21:107.
- Platten M, Nollen EAA, Röhrig UF, et al. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. *Nat Rev Drug Discov* 2019;18:379–401.
- Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. *J Interferon Cytokine Res* 2003;23:413–21.
- Lood C, Tydén H, Gullstrand B, et al. Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus. *PLoS One* 2015;10:e0125109.
- Kim H, Chen L, Lim G, et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. *J Clin Invest* 2012;122:2940–54.
- Carlin JM, Borden EC, Sondel PM, et al. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. *J Leukoc Biol* 1989;45:29–34.
- Ozaki Y, Edelstein MP, Duch DS. The actions of interferon and anti-inflammatory agents of induction of indoleamine 2,3-dioxygenase in human peripheral blood monocytes. *Biochem Biophys Res Commun* 1987;144:1147–53.
- Guillemin GJ, Smith DG, Smythe GA, et al. Expression of the kynurenine pathway enzymes in human microglia and macrophages. *Adv Exp Med Biol* 2003;527:105–12.
- Espey MG, Chernyshev ON, Reinhard JF, et al. Activated human microglia produce the excitotoxin quinolinic acid. *Neuroreport* 1997;8:431–4.
- Pan W, Banks WA, Kastin AJ. Permeability of the blood-brain and blood-spinal cord barriers to interferons. *J Neuroimmunol* 1997;76:105–11.
- Fukui S, Schwarcz R, Rapoport SI, et al. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. *J Neurochem* 1991;56:2007–17.
- Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. *Mol Psychiatry* 2010;15:393–403.
- Saito K, Crowley JS, Markey SP, et al. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. *J Biol Chem* 1993;268:15496–503.
- Valle M, Price RW, Nilsson A, et al. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. *Brain* 2004;127:1047–60.
- Chi JM, Mackay M, Hoang A, et al. Alterations in blood-brain barrier permeability in patients with systemic lupus erythematosus. *AJNR Am J Neuroradiol* 2019;40:470–7.
- Kamintsky L, Beyea SD, Fisk JD, et al. Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment. *Ann Rheum Dis* 2020;79:1580–7.
- Aw E, Zhang Y, Carroll M. Microglial responses to peripheral type 1 interferon. *J Neuroinflammation* 2020;17:340.
- Gulaj E, Pawlak K, Bien B, et al. Kynurenine and its metabolites in alzheimer's disease patients. *Adv Med Sci* 2010;55:204–11.
- Gill LM, Midttun Øivind, Refsum H, et al. Kynurenine pathway metabolites in alzheimer's disease. *J Alzheimers Dis* 2017;60:495–504.
- Savitz J. Role of kynurenine metabolism pathway activation in major depressive disorders. *Curr Top Behav Neurosci* 2017;31:249–67.
- Stone TW, Darlington LG. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. *Br J Pharmacol* 2013;169:1211–27.
- Vogelgesang SA, Heyes MP, West SG, et al. Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations. *J Rheumatol* 1996;23:850–5.
- Anderson EW, Fishbein J, Hong J, et al. Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus. *Lupus Sci Med* 2021;8:e000559.
- Åkesson K, Pettersson S, Ståhl S, et al. Kynurenine pathway is altered in patients with SLE and associated with severe fatigue. *Lupus Sci Med* 2018;5:e000254.
- Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. *N Engl J Med* 2020;382:211–21.
- Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. *Arthritis Rheumatol* 2014;66:1583–95.
- Chiarugi A, Calvani M, Meli E, et al. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. *J Neuroimmunol* 2001;120:190–8.
- Jones SP, Franco NF, Varney B, et al. Expression of the kynurenine pathway in human peripheral blood mononuclear cells: implications for inflammatory and neurodegenerative disease. *PLoS One* 2015;10:e0131389.
- Orhan F, Bhat M, Sandberg K, et al. Tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor stimulation in peripheral monocytes. *Scand J Immunol* 2016;84:262–71.
- Godin-Ethier J, Hanafi L-A, Duvignaud J-B, et al. IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive. *Mol Immunol* 2011;49:253–9.
- Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:40.
- Petri M, Orbai A-M, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012;64:2677–86.
- Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. *Lupus* 1999;8:685–91.

- 37 Mackay M, Vo A, Tang CC, *et al*. Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. *JCI Insight* 2019;4. doi:10.1172/jci.insight.124002. [Epub ahead of print: 10 Jan 2019].
- 38 Beck AT, Steer RA, Brown GK. *BDI-II, Beck depression inventory : manual*. 2nd ed. San Antonio, Tex: Boston: Psychological Corp.; Harcourt Brace, 1996: vi, 38.
- 39 Dobin A, Davis CA, Schlesinger F, *et al*. Star: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29:15–21.
- 40 Liao Y, Smyth GK, Shi W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 2014;30:923–30.
- 41 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
- 42 Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using david bioinformatics resources. *Nat Protoc* 2009;4:44–57.
- 43 Arazi A, Rao DA, Berthier CC, *et al*. The immune cell landscape in kidneys of patients with lupus nephritis. *Nat Immunol* 2019;20:902–14.
- 44 Rusinova I, Forster S, Yu S, *et al*. Interferome v2.0: an updated database of annotated interferon-regulated genes. *Nucleic Acids Res* 2013;41:D1040–6.
- 45 Newman AM, Steen CB, Liu CL, *et al*. Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nat Biotechnol* 2019;37:773–82.
- 46 Kong Y, Rastogi D, Seoighe C, *et al*. Insights from deconvolution of cell subtype proportions enhance the interpretation of functional genomic data. *PLoS One* 2019;14:e0215987.
- 47 Panousis NI, Bertias GK, Ongen H, *et al*. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. *Ann Rheum Dis* 2019;78:1079–89.
- 48 Mohammadi S, Sedighi S, Memarian A, *et al*. Overexpression of interferon- $\gamma$  and indoleamine 2, 3-dioxygenase in systemic lupus erythematosus: relationship with the disease activity. *LaboratoriumsMedizin* 2017;41:41–7.
- 49 Furuzawa-Carballeda J, Lima G, Jakez-Ocampo J, *et al*. Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study. *Eur J Clin Invest* 2011;41:1037–46.
- 50 Gostner JM, Schröcksnadel S, Becker K, *et al*. Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC. *FEBS Open Bio* 2012;2:241–5.
- 51 Schroecksnadel S, Sucher R, Kurz K, *et al*. Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells. *Transpl Immunol* 2011;25:119–23.
- 52 Nehar-Belaid D, Hong S, Marches R, *et al*. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. *Nat Immunol* 2020;21:1094–106.
- 53 Perez RK, Gordon MG, Subramaniam M, *et al*. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. *Science* 2022;376:eabf1970.
- 54 Dai W, Gupta SL. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. upstream control region discriminates between interferon-gamma and interferon-alpha. *J Biol Chem* 1990;265:19871–7.
- 55 Kita T, Morrison PF, Heyes MP, *et al*. Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain. *J Neurochem* 2002;82:258–68.
- 56 Zwilling D, Huang S-Y, Sathyaikumar KV, *et al*. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. *Cell* 2011;145:863–74.
- 57 Haroon E, Welle JR, Woolwine BJ, *et al*. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. *Neuropsychopharmacology* 2020;45:998–1007.
- 58 Jacobs KR, Lim CK, Blennow K, *et al*. Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in alzheimer's disease and relationship to amyloid- $\beta$  and tau. *Neurobiol Aging* 2019;80:11–20.
- 59 Libre A, Bondet V, Rodero MP, *et al*. Development and validation of an ultrasensitive single molecule array digital enzyme-linked immunosorbent assay for human interferon- $\alpha$ . *J Vis Exp* 2018. doi:10.3791/57421. [Epub ahead of print: 14 06 2018].
- 60 Steen CB, Liu CL, Alizadeh AA, *et al*. Profiling cell type abundance and expression in bulk tissues with CIBERSORTx. *Methods Mol Biol* 2020;2117:135–57.
- 61 Lugo-Huitrón R, Ugalde Muñiz P, Pineda B, *et al*. Quinolinic acid: an endogenous neurotoxin with multiple targets. *Oxid Med Cell Longev* 2013;2013:1–14.
- 62 Kolde R. Package 'pheatmap'. Bioconductor 1–6, 2012. Available: <https://CRAN.R-project.org/package=pheatmap>
- 63 R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria R Foundation for Statistical Computing; 2011.

## Supplementary Data

**Supplemental Table 1: List of 144 Genes that Positively Correlated with the KYN/TRP Ratio.** The first 71 listed genes, in **bold**, indicate interferon-stimulated genes. Gene ontology (GO) of the remaining 73 genes that correlated with the KYN/TRP ratio revealed genes associated with cell movement, including microtubules and motile cilia; notably, increased kynurenine has been associated with increased expression of cytoskeletal proteins that enhance cell motility in mice.[1] The GO analysis also revealed genes involved in muscle tissue generation and organization, as well as embryo implantation.

Gene	$r_s$	p
<b>ACVRL1</b>	0.267	0.023
<b>ATF3</b>	0.344	0.003
<b>BST2</b>	0.397	0.001
<b>C1QA</b>	0.300	0.010
<b>C1QB</b>	0.326	0.005
<b>C1QC</b>	0.294	0.012
<b>CDK1</b>	0.294	0.012
<b>CRYM</b>	0.282	0.016
<b>DHX58</b>	0.262	0.026
<b>EPSTI1</b>	0.274	0.020
<b>ETV7</b>	0.321	0.006
<b>EXOC3L1</b>	0.297	0.011
<b>FBXO6</b>	0.247	0.037
<b>GBP1</b>	0.261	0.027
<b>GBP1P1</b>	0.295	0.012
<b>HBQ1</b>	0.304	0.009
<b>HERC6</b>	0.263	0.026
<b>HES4</b>	0.385	0.001
<b>HESX1</b>	0.233	0.049
<b>HIST1H2BO</b>	0.272	0.021
<b>HIST1H4H</b>	0.307	0.009
<b>IFI27</b>	0.367	0.002
<b>IFI35</b>	0.290	0.013
<b>IFI44</b>	0.244	0.039
<b>IFI44L</b>	0.299	0.011
<b>IFI6</b>	0.342	0.003
<b>IFIT1</b>	0.238	0.044
<b>IFIT1B</b>	0.233	0.049
<b>IFIT3</b>	0.254	0.031
<b>IFITM1</b>	0.284	0.016
<b>IFITM3</b>	0.234	0.048
<b>IRF7</b>	0.319	0.007
<b>ISG15</b>	0.315	0.007
<b>KLHDC7B</b>	0.356	0.002

LAP3	0.283	0.016
LGALS3BP	0.290	0.014
LRRC2	0.406	<0.001
LY6E	0.267	0.024
MDK	0.238	0.044
MOV10	0.356	0.002
MS4A4A	0.297	0.011
MT2A	0.402	<0.001
MX1	0.242	0.041
NEXN	0.295	0.012
NRN1	0.252	0.033
OAS1	0.330	0.005
ODF3B	0.317	0.007
PARP10	0.299	0.011
PARP12	0.265	0.024
PTTG1	0.256	0.030
RMI2	0.360	0.002
RTP4	0.307	0.009
SCO2	0.370	0.001
SERPING1	0.268	0.023
SGIP1	0.266	0.024
SIGLEC1	0.237	0.045
SPATS2L	0.286	0.015
STAT2	0.236	0.046
TIMM10	0.335	0.004
TK1	0.344	0.003
TMCC2	0.319	0.006
TMEM45A	0.265	0.024
TPX2	0.248	0.036
TREX1	0.355	0.002
TRHDE-AS1	0.238	0.044
UBE2L6	0.269	0.022
UBQLNL	0.260	0.027
USP18	0.268	0.023
USP41	0.270	0.022
XAF1	0.302	0.010
ZNF684	0.251	0.033
ABCC13	0.288	0.014
AC007016.3	0.267	0.023
AC067945.3	0.371	0.001
AC068831.16	0.246	0.038
AC074338.4	0.275	0.019
ACOD1	0.298	0.011

AL137860.1	0.258	0.029
ANO7P1	0.372	0.001
AP000662.4	0.297	0.011
AP001627.1	0.250	0.034
BISPR	0.309	0.008
CDH6	0.238	0.044
CKAP2L	0.328	0.005
CRAT37	0.332	0.004
CTA-384D8.31	0.277	0.018
CTA-384D8.35	0.281	0.017
CTA-384D8.36	0.350	0.003
CTD-2047H16.2	0.287	0.015
CTD-2095E4.5	0.233	0.049
CTD-2521M24.13	0.248	0.036
CTD-2521M24.4	0.341	0.003
CTD-2521M24.8	0.359	0.002
CTD-2561J22.5	0.304	0.009
FAM155B	0.294	0.012
GAPDHP66	0.263	0.026
GTSE1	0.252	0.033
HBM	0.369	0.001
HCG9	0.289	0.014
HMP19	0.267	0.024
IFITM9P	0.305	0.009
KLC3	0.311	0.008
LA16c-17H1.3	0.273	0.020
LARP1P1	0.279	0.018
LIF	0.390	0.001
LINC01296	0.251	0.033
LLNLR-271C9.1	0.267	0.023
MAFA	0.254	0.032
MTND3P10	0.265	0.024
MTND4LP14	0.245	0.038
MTND4P26	0.254	0.032
MYBL2	0.272	0.021
NRIR	0.263	0.025
OLFM5P	0.232	0.049
OR2B6	0.242	0.040
OR51AB1P	0.375	0.001
OR52B3P	0.248	0.036
RABGAP1L-IT1	0.270	0.022
RNY3P8	0.279	0.018
RP1-221C16.8	0.255	0.031

RP1-71H24.1	0.330	0.005
RP1-99E18.2	0.245	0.038
RP11-20D14.6	0.350	0.003
RP11-273G15.2	0.334	0.004
RP11-288L9.1	0.411	0.000
RP11-288L9.4	0.234	0.048
RP11-54O7.17	0.348	0.003
RP11-560F18.1	0.262	0.026
RP11-609D21.3	0.315	0.007
RP11-77H9.8	0.234	0.048
RP3-449M8.9	0.246	0.037
RP3-467D16.3	0.459	0.000
RP4-718J7.4	0.235	0.047
RUNDC3A	0.322	0.006
RUNDC3A-AS1	0.272	0.021
SMTNL1	0.249	0.035
TEKT1	0.260	0.027
THEM5	0.236	0.046
TMEM56	0.237	0.045
TPRG1-AS1	0.247	0.037
TROAP	0.319	0.006
UNC93B3	0.285	0.015
XK	0.233	0.049
ZDHHC4P1	0.276	0.019

**Supplemental Table 2: List of 81 Genes that Positively Correlated with the QA/KA Ratio.** The first 38 listed genes, in **bold**, indicate interferon-stimulated genes.

Gene	$r_s$	$p$
<b>ATF3</b>	0.250	0.034
<b>BCL2L14</b>	0.345	0.003
<b>C2orf66</b>	0.301	0.010
<b>CCL2</b>	0.370	0.001
<b>CCL8</b>	0.495	<0.001
<b>CCNA1</b>	0.260	0.028
<b>CCNB2</b>	0.268	0.023
<b>CDCA2</b>	0.239	0.043
<b>CDK1</b>	0.311	0.008
<b>CXCL10</b>	0.278	0.018
<b>DLGAP5</b>	0.283	0.016
<b>DTL</b>	0.278	0.018
<b>E2F8</b>	0.390	0.001
<b>EMP1</b>	0.283	0.016
<b>EPHB2</b>	0.261	0.027
<b>IGHV4-59</b>	0.257	0.029
<b>IGHV4-61</b>	0.243	0.040
<b>IGKV1-17</b>	0.284	0.015
<b>IGKV1D-33</b>	0.248	0.036
<b>IL10</b>	0.254	0.031
<b>KCTD14</b>	0.270	0.022
<b>KLHDC7B</b>	0.327	0.005
<b>LAMP3</b>	0.250	0.034
<b>LAP3</b>	0.233	0.049
<b>LIF</b>	0.340	0.004
<b>MCM10</b>	0.327	0.005
<b>MELK</b>	0.276	0.019
<b>MOXD1</b>	0.258	0.029
<b>MS4A4A</b>	0.345	0.003
<b>MT1E</b>	0.249	0.035
<b>NKAIN1</b>	0.259	0.028
<b>PBK</b>	0.273	0.020
<b>RMI2</b>	0.236	0.046
<b>RRM2</b>	0.293	0.013
<b>RUFY4</b>	0.255	0.030
<b>SDC1</b>	0.279	0.018
<b>SLC12A8</b>	0.410	<0.001
<b>SOCS1</b>	0.276	0.019
AC006160.5	0.342	0.003

AP001626.1	0.259	0.028
C1orf226	0.245	0.038
CAV1	0.246	0.037
CDC20P1	0.256	0.030
CDC42P3	0.420	<0.001
CDC45	0.265	0.025
CEP55	0.296	0.012
CKAP2L	0.289	0.014
CTA-384D8.31	0.283	0.016
DLGAP1	0.238	0.044
IGFL2	0.370	0.001
IGKJ3	0.266	0.024
IGKV1-33	0.255	0.031
IGKV1-6	0.267	0.024
IGKV1-8	0.259	0.028
IGKV1D-8	0.269	0.023
IGKV2-40	0.245	0.038
IGKV2D-40	0.248	0.036
IGKV3D-20	0.242	0.041
IGLJ6	0.256	0.030
IGLJ7	0.308	0.009
IGLV1-40	0.253	0.032
IGLV1-50	0.251	0.034
IGLV2-28	0.288	0.014
IGLV3-1	0.236	0.046
IGLV5-37	0.319	0.006
IGLV6-57	0.271	0.022
IQGAP3	0.241	0.041
LIPM	0.272	0.021
MAP6	0.267	0.023
MT2P1	0.262	0.026
PTGFR	0.233	0.049
RGS13	0.278	0.018
RP11-10L7.1	0.334	0.004
RP11-239E10.2	0.276	0.019
RP11-439M11.1	0.260	0.027
RP11-466G12.3	0.237	0.045
SKA1	0.318	0.007
TICRR	0.235	0.047
TMEM178B	0.370	0.001
TTK	0.334	0.004
TYMSOS	0.396	0.001

**Reference**

1. Moffett JR, Arun P, Puthillathu N, et al. Quinolate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD(+) Synthesis During Inflammation and Infection. *Front Immunol* 2020;11:31.

## Supplementary Methods

### A. Measurement of the Kynurenine/Tryptophan (KYN/TRP) Pathway Metabolites

#### *LC-MS/MS analysis of KYN, TRP, and kynurenic acid (KA)*

KYN-D<sub>4</sub>, TRP-D<sub>5</sub>, and KA-D<sub>5</sub> were used as internal standards (IS). Serum samples were prepared for analysis by a transfer of 10 µL sample, followed by the addition of 90 µL precipitation solution (acetonitrile/H<sub>2</sub>O 8:2 with 0.1% formic acid and 0.01% ascorbic acid) containing IS. After vortexing, samples were centrifuged for 5 minutes at 4°C and 13,000 rpm, and 10 µL of supernatant was diluted 10-fold with 90 µL of ultrapure water with 0.1% (v/v) formic acid and 0.01% (w/v) ascorbic acid.

Samples were injected by a SIL20-AD autosampler (Shimadzu, Japan) onto an Atlantis T3 C18 High Performance Liquid Chromatography (HPLC) column (2.1\*150 mm, 3.0 µm particle size; Waters, USA), held at 25°C. Mobile phase A consisted of ultrapure water with 0.1% FA. Mobile phase B was acetonitrile with 0.1% FA. Elution of the compounds was performed using a linear gradient at a flow rate of 0.2 mL/minute using the Infinity 1290 HPLC system (Agilent, USA). The HPLC system was connected to a QTrap 5500® mass spectrometer (Sciex, USA) equipped with a Turbo Ion Spray interface.

The acquisitions on the QTrap® 5500 were performed in positive ionization mode, with optimized settings for the analytes. The instrument was operated in multiple reaction-monitoring (MRM) mode. Data were calibrated and quantified using the Analyst™ data system (Sciex, version 1.5.2).

#### *LC-MS/MS analysis of quinolinic acid (QA)*

QA-D<sub>3</sub> was used as an IS. Serum samples were prepared for analysis by a transfer of 10 µL sample, followed by the addition of 40 µL precipitation solution (acetonitrile/H<sub>2</sub>O 8:2) containing IS. After vortexing, samples were centrifuged for 5 minutes at 4°C and 13,000 rpm, and 5 µL of supernatant was diluted with 50 µL of ultrapure water with 0.1% (v/v) formic acid and 0.01% (w/v) ascorbic acid.

Samples were injected by a SIL 10ADvp autosampler (Shimadzu, Japan) onto a Synergi Max-RP HPLC column (3.0\*100 mm, 2.5 µm particle size; Phenomenex, USA), held at 20°C. Mobile phase A consisted of ultrapure water with 0.2% TFA. Mobile phase B was acetonitrile with 0.2% TFA. Elution of the compound was performed using a linear gradient at a flow rate of 0.3 mL/minute using the LC-20ADxr HPLC system (Shimadzu, Japan). The HPLC system was connected to an API 4000® triple quadrupole mass spectrometer (Sciex, USA) equipped with a Turbo Ion Spray interface.

The acquisitions on the API 4000® mass spectrometer were performed in positive ionization mode, with optimized settings for the analytes. The instrument was operated in MRM mode. Data were calibrated and quantified using the Analyst™ data system (Sciex, version 1.4.2).

### B. RNA Sequencing (RNAseq)

#### *RNA isolation and quality control measures*

De-identified, blinded whole blood samples in PAXgene Blood RNA tubes were received by Cold Spring Harbor Laboratory, and left out overnight at room temperature. RNA was extracted using the PAXgene RNA Kit, according to instructions exactly as written in the manufacturer's protocol. A subset of the samples was tested for quality determined by RNA Integrity Number (RIN) score using the RNA Nano Kit on a BioAnalyzer by Agilent Technologies.

After the blood RNA extraction, quality control was performed on all the RNA samples using the RNA assay for Qubit fluorometer (Thermo Fisher Scientific). A subset of the samples was run using the Agilent Femto RNA assay.

#### *Library Preparation and RNAseq Technique*

The kapa mRNA HyperPrep kit Illumina Platforms were used for library preparation. This protocol is suitable for the construction of high-quality libraries from 50 ng to 1 µg of total intact RNA. The amount of starting material was 100 ng high quality RNA in 50 µL of RNase-free water, and fragment sizes of ~ 450 base

pair were targeted (6 minutes at 85°C incubation). For the library amplification step, 13 cycles of PCR were performed.

Post-enrichment, the libraries were evaluated using the DNA HS assay on Qubit and the DNA HS Bioanalyzer assay, and then libraries were pooled based on nM concentration. The final pools were quantified using the kapa qPCR library quantification protocol, and then loaded on the Illumina NextSeq500 instrument. Sequencing runs were performed as single-end 76 base pair high outputs.

### C. Identification of Interferon-Stimulated Genes (ISG)

*Identification of ISG in the Interferome Database (Rusinova I et al Interferome v2.01, 2013)[1]*

The filter in Interferome was set as previously described in Chiche et al[2], “Supplemental Methods, Interferome database:” experiment type: *in vitro*, species: human, organ: all except fetal brain, embryo, umbilical vein. Genes were defined as ISG if they were responsive to at least one type of interferon (IFN) with fold change (FC) expression > 2 compared to baseline after *in vitro* stimulation with IFN, as previously described (Chiche et al).

### D. IFN scores

IFN scores were derived using methods for quantification of ISG expression and ISG selection:

#### 1. Quantification of individual ISG expression:

- Z-scores of normalized and variance stabilized gene expression were calculated as:

$$\frac{\text{Expression of the gene of interest} - \text{HC mean expression of the gene of interest}}{\text{HC standard deviation (SD) of the expression of the gene of interest}}$$

- The “Z-IFN score” for each subject was then calculated as the mean of Z-scores for each of the genes of interest for each subject.

#### 2. ISG selection:

The “ISGs of interest” used to compute an IFN score for each subject were selected by 2 approaches:

- **Approach 1** included 110 ISG reported by Arazi et al in their studies of single cell RNAseq analysis of IFN response in infiltrating cells in lupus nephritis. Of these 110 ISGs, 96 are co-expressed in the IFN modules reported by Chiche et al.
- **Approach 2** included 19 ISGs from the 110 ISG included in Approach 1 that are more responsive to type I IFN than type II IFN, according to the modules of co-expressed ISG described in Chiche et al. (Module 1.2).

### **References**

1. Rusinova I, Forster S, Yu S, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. *Nucleic Acids Res* 2013;41:D1040-6.
2. Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. *Arthritis Rheumatol* 2014;66:1583-95.